Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
26.87
+1.18 (4.59%)
At close: Aug 13, 2025, 4:00 PM
26.92
+0.05 (0.19%)
After-hours: Aug 13, 2025, 7:57 PM EDT
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$4,692,314
Market Cap
19.96B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 159 | 54 | 51.43% |
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SMMT News
- 2 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Business Wire
- 4 weeks ago - SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 5 weeks ago - Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain - Seeking Alpha
- 6 weeks ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire
- 2 months ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 2 months ago - Summit Therapeutics: Market Overreaction Creates Opportunity - Seeking Alpha
- 2 months ago - Is SMMT Stock A Buy After Its Recent Plunge? - Forbes